ASTRAZENECA $50.19

down -0.79


19/6/2013 04:19 PM  |  NYSE : AZN  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Get Trend Analysis Icon Get AZN Trend Analysis - it has underperformed the S&P 500 by 3%

Partner Headlines

  1. AstraZeneca, Pharma Laggard, Shaking Up Its R&D Team

    YCharts

  2. Do Pharma Stocks Deserve Takeover Premiums? Read This First

    YCharts

  3. Patent Victory Gives AstraZeneca Time to Develop New Drugs: Bad News?

    YCharts

  4. 16 Really Cheap International Dividend Achievers

    GuruFocus

  5. Astrazeneca Says Got Updated Guidelines on Stemi

    Benzinga

  6. Clinical-Trial Flops Hurt AstraZeneca, Lilly, But Bolster Abbott

    YCharts

  7. Stocks Open Firm But Reverse Lower On Fiscal Worries

    Investors Business Daily

  8. Stocks Near Lows In Late Trading; Drug Stocks Sink

    Investors Business Daily

  9. Stocks Hold Near Lows; AstraZeneca, Eli Lilly Sink

    Investors Business Daily

  10. Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary ...

    Benzinga

  11. AstraZeneca, Lilly Arthritis Drugs Flop In Trials

    Investors Business Daily

  12. Par Pharma Begins Shipping Generic Atacand HCT

    Benzinga

  13. Appeals Court Ruling on Off-Label Drug Marketing: What it Means

    YCharts

  14. From Earlier: Optimer, AstraZeneca Collaborate to Commercialize ...

    Benzinga

  15. Pfizer, Stock Rising on Cost Cuts, Plans More Staff Layoffs

    YCharts

  16. Dynavax: Little Stock With a Big Story – Plunge a Buy Opportunity?

    YCharts

  17. An Anti-Psychotic Drug With its Own Issues: AstraZeneca's Seroquel ...

    YCharts

  18. Nektar Therapeutics Plunges on FDA Worries, Downgrade

    Benzinga

  19. AstraZeneca Announces Positive Phase III Results from Naloxegol ...

    Benzinga

  20. Study on AZN's Seroquel Might Have Warned Pentagon Off Big Use of ...

    YCharts

  21. Take an Out-of-Work Drug Rep to Lunch: More Big Pharma Layoffs

    YCharts

  22. Myriad Genetics Stock Hits High On Earnings Beat

    Investors Business Daily

  23. Merck's Mighty Januvia: The Diabetic Investor Explains a Huge, ...

    YCharts

  24. Cures Looking For Diseases: AstraZeneca Opens Its Old-Drug Closet ...

    YCharts

  25. Stock Averages Advance Modestly In Mixed Turnover

    Investors Business Daily

  26. 15 of the Cheapest High-Yield Large Caps to Consider

    GuruFocus

  27. Stocks Climb In Mixed Trade; Three D Systems Gaps Up

    Investors Business Daily

  28. Pharma's Pay-to-Delay Deals Boost Healthcare Costs (and Pharma ...

    YCharts

  29. Benzinga's M&A Chatter for Wednesday October 3, 2012

    Benzinga

  30. Merck's $1 Billion-a-Year Gardasil Vaccine Garners Another Safety ...

    YCharts

  31. Is New AstraZeneca CEO Looking For Big Acquisitions?

    YCharts

  32. Benzinga's M&A Chatter for Monday October 1, 2012

    Benzinga

  33. A Big Part of the Pharma Pipeline is Struggling: Biotech Startups

    YCharts

  34. Pharma Profits Bottoming Out, Moody's Forecasts

    YCharts

  35. Benzinga's Top Upgrades

    Benzinga

  36. Alkermes Writes New Prescription For Growth

    Investors Business Daily

  37. What's Pharma R&D Really Producing? Another Take on the Weak Drug ...

    YCharts

  38. Confused by Pharma Stocks' Hefty Dividends, Weak Drug Pipeline? ...

    YCharts

  39. Pharma Trouble: Drug Approvals at FDA Could Slow or Halt Due to ...

    YCharts

  40. UPDATE: Bank of America Downgrades AstraZeneca to Underperform ...

    Benzinga

  41. Seven Cheap Large-Caps Yielding Over 4%

    Benzinga

  42. Can the Roche Guy Turn Around AstraZeneca?

    YCharts

  43. AstraZeneca Nabs Roche Exec as New CEO

    FOXBusiness

  44. AstraZeneca Appoints Pascal Soriot As New CEO

    Benzinga

  45. Parkinson's Drug Awaits OK While ADHD Lifts Impax Now

    Investors Business Daily

  46. Myriad Genetics Reports In-Line Q4, But Costs To Rise

    Investors Business Daily

  47. Pfizer

    Investors Business Daily

  48. AstraZeneca sepsis drug fails

    Investors Business Daily

  49. AstraZeneca (AZN) Up 0.3% Ahead of Going Ex-Dividend Tomorrow

    At Market Intelligence Center

  50. Impax Labs In Buying Range After Topping 23.33 Entry

    Investors Business Daily

  51. Four Investment Options Presented by Obesity and Related Health ...

    YCharts

  52. 10 Best Yielding Drug Manufacturing Stocks

    GuruFocus

  53. U.S. Charges 48 People in $500M Medicaid Drug Scheme

    FOXBusiness

  54. BRILINTA Receives Additional Class I Recommendation in Updated ...

    Benzinga

  55. Health Care Sector Wrap

    FOXBusiness

  56. AstraZeneca Acquires Neuroscience Assets From Link Medicine; Terms ...

    Benzinga

  57. Bristol-Myers Pays $7 Billion For Diabetes Drug Maker: Good Deal?

    YCharts

  58. AstraZeneca (AZN) Gains 1.5% on TB Partnership

    At Market Intelligence Center

  59. Bristol-Myers to Acquire Amylin

    Benzinga

  60. Amylin Stock Surges On Bristol-Myers Acquisition

    Investors Business Daily

  61. Bristol-Myers Buys Diabetes-Focused Amylin for $5.3B

    FOXBusiness

  62. Stock Futures Turn Mixed; SXC Health Backtracks

    Investors Business Daily

  63. AstraZeneca And Cellworks Collaborate To Find New Treatment For ...

    Benzinga

  64. Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for $31/Share

    Benzinga

  65. AstraZeneca (AZN) Gains 1% As European Stocks Climb after EU Agreement

    At Market Intelligence Center

  66. Costco Wholesale, EnCana Corporation Among Stocks Up on High ...

    FOXBusiness

  67. J.P. Morgan Cazenove Reiterates Neutral Rating for AstraZeneca

    Benzinga

  68. A Peek Into The Market Before The Trading Starts

    Benzinga

  69. Merck and AstraZeneca Agree to Amend Partnership

    Benzinga

  70. 20 Best Yielding Stocks From Europe With Safe Heaven Aspects

    GuruFocus

  71. Pharma-Karma: $1 Billion Fines No Biggie for Illegally Promoting ...

    YCharts

  72. Amylin Shares Jump as Sanofi, Merck Sumbit Bids

    Benzinga

  73. GlaxoSmithKline to Get Hostile with Offer for Human Genome

    Benzinga

  74. AstraZeneca (AZN) Loses 6% On Weak Earnings, CEO resignation

    At Market Intelligence Center

  75. AstraZeneca's CEO Quits As Earnings, Revenue Drop

    at IBD

  76. Several medical deals inked

    at IBD

  77. Medicals Lead M&A Monday

    at IBD

  78. Stocks Slip on Europe, China Fears with Kellogg (K) and D.R. ...

    At Market Intelligence Center

  79. AstraZeneca (AZN) Up 1.6% as Volatile Trading Continues

    At Market Intelligence Center

  80. Amgen

    at IBD

  81. AstraZeneca

    at IBD

  82. AstraZeneca

    at IBD

  83. Benzinga's M&A Chatter for Thursday March 8, 2012

    at Benzinga

  84. Eight Drug Majors Sued Over Use Of Co-Pay Coupons

    at IBD

  85. Find High-Yield Retirement Income From Other Sources

    at IBD

  86. Top 20 New Magic Formula Stocks from Joel Greenblatt

    at GuruFocus

  87. AstraZeneca Announces First Direct-to-Patient Program Offering the ...

    at Benzinga

  88. AstraZeneca (AZN) Down 0.3%, Sees 2x Normal Call Volume

    At Market Intelligence Center

  89. Notable Call Options Activity in AstraZeneca

    at Benzinga

  90. Gilead EPS Misses, Share Dip

    at IBD

  91. Notable Put Options Activity in AstraZeneca

    at Benzinga

  92. Stock Futures Climb; Cummins Gains On Q4 Beat

    at IBD

  93. AstraZeneca To Cut 7,300 Jobs, Projects Drop In Profit

    at Benzinga

  94. Ken Fisher and the Price to Research Ratio

    at GuruFocus

  95. Bristol Myers Q4 Profit, Sales Below Expectations

    at IBD

  96. FDA postpones diabetes drug

    at IBD

  97. Bristol-Myers, AstraZeneca Diabetes Drug Delayed

    at IBD

  98. Notable Call Options Activity in AstraZeneca

    at Benzinga

  99. Share buyback champions with positive FCF and dividend yields of ...

    at GuruFocus

  100. Novartis latest pharma to cut

    at IBD
People viewing AZN also viewed: , , , , , ,
Marketplace
Trading Center